They just gone thru their year-end process and their business model can’t be more straight forward with zero debt. They don’t even sell their own products and are not getting any other non royalty related income other than interest income. So chance of delay is because of accounting issue seems remote.
If they are indeed going to do a restructure and make the company officially focus on only immunology plus RSV (I assume they will incur cost for staff cut and asset write off etc). I wish they just auction off all the other virology assets include 235 and all related IP. Get whatever they can and move on.
Now looking back, maybe that’s why they removed hpv and 235 partnership from their business goals in latest update.
Market Data 
Markets 
AI
